LOS ANGELES, Dec. 6, 2017 /PRNewswire/ -- CytRx
Corporation (NASDAQ: CYTR), a biopharmaceutical research and
development company specializing in oncology, today announced that
it has filed provisional patent applications covering two series of
drug candidates from its LADR™ (Linker Activated Drug Release)
Technology Platform. The newly filed applications cover
compounds, pharmaceutical compositions and methods of use thereof.
When granted, these new patents will expand CytRx's
intellectual property estate and the Company will own worldwide
rights for each.
"These newly filed patent applications cover LADR™ drug
conjugates with two distinct classes of ultra-highly potent
cytotoxic payloads," said Steven A.
Kriegsman, CytRx's Chairman and CEO. "A strong patent
estate is at the core of our business model and strengthens our
competitive advantage in the marketplace, and we intend to leverage
the LADR™ technology with potential pharmaceutical and
biotechnology partners. When granted, these newly filed
patent applications will significantly strengthen our intellectual
property portfolio and support the ongoing development of our
cutting-edge LADR technology assets which have the potential to
improve outcomes for patients with cancer."
Felix Kratz, PhD, CytRx's Vice
President of Drug Discovery commented, "The LADR™ platform is a
discovery engine designed to create a pipeline of anti-cancer
molecules that will avoid unacceptable systemic toxicity while
delivering high potency agents directly to the tumor. We are
awaiting final toxicology results from four lead compounds in order
to nominate one or more candidates for advancement into
Investigational New Drug (IND) enabling preclinical studies.
We look forward to announcing our selection during the first
quarter of 2018 and to presenting data on these new candidates with
the medical community at a major scientific meeting in 2018."
About the LADR™ Technology Platform
CytRx's innovative LADR™ (Linker Activated Drug Release)
technology employs a broad portfolio of novel linker molecules that
selectively bind to circulating albumin and can be linked to a wide
variety of anti-cancer payloads. The Company's research
efforts currently center on creating new molecules from the
combination of ultra-high potency cytotoxic payloads with tunable
linkers. The molecules that CytRx is currently evaluating
concentrate at the tumor site providing targeted delivery of the
cell killing payloads.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical company specializing in
research and clinical development of novel anti-cancer drug
candidates that employ linker technologies to enhance the
accumulation and release of drug at the tumor. CytRx is also
rapidly expanding its pipeline of ultra-high potency oncology
candidates at its laboratory facilities in Freiburg, Germany,
through its LADR™ (Linker Activated Drug Release) technology
platform, a discovery engine designed to leverage CytRx's expertise
in albumin biology and linker technology for the development of a
new class of potential breakthrough anti-cancer therapies.
Aldoxorubicin, CytRx's most advanced drug conjugate, is an
improved version of the widely used anti-cancer drug doxorubicin
and has been out-licensed to NantCell, Inc.
Forward-Looking Statements
This press release contains forward-looking statements. Such
statements involve risks and uncertainties that could cause actual
events or results to differ materially from the events or results
described in the forward-looking statements, including risks and
uncertainties relating to plans for regaining compliance with the
Nasdaq rules and higher share price of our common stock; the
ability of NantCell, Inc., to obtain regulatory approval for its
products that use aldoxorubicin; the ability of NantCell, Inc., to
manufacture and commercialize products or therapies that use
aldoxorubicin; the amount, if any, of future milestone and royalty
payments that we may receive from NantCell, Inc.; our ability to
develop new ultra-high potency drug candidates based on our
LADRTM technology platform; and other risks and
uncertainties described in the most recent annual and quarterly
reports filed by CytRx with the Securities and Exchange Commission
and current reports filed since the date of CytRx's most recent
annual report. All forward-looking statements are based upon
information available to CytRx on the date the statements are first
published. CytRx undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:
Argot Partners
Michelle Carroll
(212) 600-1902
michelle@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/cytrx-corporation-announces-filing-of-key-provisional-patent-applications-for-ultra-high-potency-ladr-drug-candidates-300567395.html
SOURCE CytRx Corporation